BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Missouri State University/Calendar of Events//EN
CALSCALE:GREGORIAN
X-WR-TIMEZONE:America/Chicago
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
DTSTART:20070311T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
TZNAME:CDT
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
DTSTART:20071104T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
TZNAME:CST
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:dae7d732-8cc6-4e9b-b529-7932bdb04c62.220280@calendar.missouristate.edu
CREATED:20220304T153218Z
LAST-MODIFIED:20220304T153218Z
LOCATION:
SUMMARY:Chemistry &amp; Biochemistry Seminar: "Protein misfolding and amyloid 
 disaggregases to counter misfolding"
DESCRIPTION:Seminar by: Dr. Meredith Jackrel\, Washington University in St
 . Louis\n\n\nThere are no therapies that reverse the aberrant liquid-liqu
 id phase separation and protein misfolding events that underpin neurodege
 nerative diseases including amyotrophic lateral sclerosis (ALS) and Parki
 nson’s disease (PD). Hsp104\, a conserved hexameric AAA+ protein from yea
 st\, solubilizes disordered aggregates and amyloid\, but has no metazoan 
 homolog and only limited activity against human neurodegenerative disease
  proteins. \n\n\nDr. Meredith Jackrel will describe the work to reprogram
  Hsp104 to rescue proteins that misfold in ALS and PD. She will also desc
 ribe efforts to better understand the mechanism of Hsp104 potentiation\, 
 enabling the engineering of variants with improved properties. Finally\, 
 she will describe the work to better understand the molecular drivers of 
 aberrant liquid-liquid phase separation and consequent aggregation\, and 
 how this process drives disease. \n\n\nJoin via Zoom.\n\n\nMeeting ID: 92
 5 1100 1032\n\n\nPasscode: 222885
X-ALT-DESC;FMTTYPE=text/html:&lt;html&gt;&lt;head&gt;&lt;title&gt;&lt;/title&gt;&lt;/head&gt;&lt;body&gt;&lt;p&gt;&lt;s
 pan&gt;Seminar by: Dr. Meredith Jackrel\, Washington University in St. Louis
 &lt;/span&gt;&lt;/p&gt;\n&lt;p&gt;&lt;span&gt;There are no therapies that reverse the aberrant li
 quid-liquid phase separation and protein misfolding events that underpin 
 neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) 
 and Parkinson’s disease (PD). Hsp104\, a conserved hexameric AAA+ protein
  from yeast\, solubilizes disordered aggregates and amyloid\, but has no 
 metazoan homolog and only limited activity against human neurodegenerativ
 e disease proteins. &lt;/span&gt;&lt;/p&gt;\n&lt;p&gt;&lt;span&gt;Dr. Meredith Jackrel&lt;/span&gt;&lt;spa
 n&gt;&amp;nbsp\;will describe&amp;nbsp\;the work to reprogram Hsp104 to rescue prote
 ins that misfold in ALS and PD.&amp;nbsp\;She will also describe efforts to b
 etter understand the mechanism of Hsp104 potentiation\, enabling the engi
 neering of variants with improved properties. Finally\,&amp;nbsp\;she will de
 scribe&amp;nbsp\;the work to better understand the molecular drivers of aberr
 ant liquid-liquid phase separation and consequent aggregation\, and how t
 his process drives disease. &lt;/span&gt;&lt;/p&gt;\n&lt;p&gt;&lt;a href="https://missouristat
 e.zoom.us/j/92511001032?pwd=NEJLRTlPL1BCV3ZiVElsSFBHOEVwZz09"&gt;Join via Zo
 om&lt;/a&gt;.&lt;/p&gt;\n&lt;p&gt;&lt;span&gt;Meeting ID: 925 1100 1032&lt;/span&gt;&lt;/p&gt;\n&lt;p&gt;&lt;span&gt;Pass
 code: 222885&lt;/span&gt;&lt;/p&gt;&lt;/body&gt;&lt;/html&gt;
DTSTART;TZID=America/Chicago:20220309T153500
DTEND;TZID=America/Chicago:20220309T162500
SEQUENCE:1
URL:
CATEGORIES:Public,Alumni,Current Students,Faculty,Future Students,Staff
END:VEVENT
END:VCALENDAR